초록 ▼

An osmotic device (10) for delivering a beneficial drug, such as an anti-fungal, into the mouth of a human patient is disclosed. The device (10) has a size and shape adapting it to be comfortably retained in the mouth for extended periods of time. The device (10) comprises a wall (12) surrounding a

An osmotic device (10) for delivering a beneficial drug, such as an anti-fungal, into the mouth of a human patient is disclosed. The device (10) has a size and shape adapting it to be comfortably retained in the mouth for extended periods of time. The device (10) comprises a wall (12) surrounding a compartment (13) housing a layer of an agent (14) that is insoluble to very soluble in aqueous biological fluids, e.g., saliva, and a layer (16) of a fluid swellable, hydrophilic polymer. A passageway (17) in the wall (12) connects the agent (14) with the exterior of the device (10). The wall (12) is permeable to the passage of aqueous biological fluid but substantially impermeable to the passage of the hydrophilic polymer (16). In one embodiment the beneficial agent (14) has a different color than the hydrophilic polymer (16). The wall (12) is sufficiently translucent to permit the patient to see the amount of drug/beneficial agent (14) remaining to be delivered. Marking lines (19) may be provided on the wall (12) indicating the amount of drug/agent (14) which has been delivered and/or the amount remaining to be delivered.

대표청구항 ▼

[ We claim:] [1.] An osmotic device for treatment of Parkinson's disease by the controlled delivery of a drug comprising levodopa to the mucosa of the oral cavity of a patient over an extended delivery period of between 0.5 to 12 hours, the device comprising:a wall defining a compartment and an exit

[ We claim:] [1.] An osmotic device for treatment of Parkinson's disease by the controlled delivery of a drug comprising levodopa to the mucosa of the oral cavity of a patient over an extended delivery period of between 0.5 to 12 hours, the device comprising:a wall defining a compartment and an exit passageway, the wall being formed of a semipermeable material;a drug layer comprising a dose of 0.05 ng to 500 mg levodopa and a suspending agent therefore located in the compartment adjacent the exit passageway, the exit passageway communicating the drug layer with the exterior, and a driving layer comprising a hydrophilic polymer located in the compartment adjacent the drug layer and opposite the exit passageway;wherein the device has a smooth oval shape with an aspect ratio in the range of about 1.2:1 to about 3:1, a height of about 0.5 to about 10 mm, and a volume of less than about 2 cm.sup.3 and delivers levodopa through the exit passageway to the mucosa within the oral cavity.